192 related articles for article (PubMed ID: 33421017)
21. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.
Todd D; Gowers I; Dowler SJ; Wall MD; McAllister G; Fischer DF; Dijkstra S; Fratantoni SA; van de Bospoort R; Veenman-Koepke J; Flynn G; Arjomand J; Dominguez C; Munoz-Sanjuan I; Wityak J; Bard JA
PLoS One; 2014; 9(2):e87923. PubMed ID: 24503862
[TBL] [Abstract][Full Text] [Related]
22. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
[TBL] [Abstract][Full Text] [Related]
23. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
24. Early Downregulation of p75
Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
[TBL] [Abstract][Full Text] [Related]
25. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
[TBL] [Abstract][Full Text] [Related]
26. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.
Wójtowicz AM; Dvorzhak A; Semtner M; Grantyn R
Front Neural Circuits; 2013; 7():188. PubMed ID: 24324407
[TBL] [Abstract][Full Text] [Related]
27. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 9 upregulates heme oxygenase-1 and gamma-glutamylcysteine synthetase expression to protect neurons from 1-methyl-4-phenylpyridinium toxicity.
Huang JY; Chuang JI
Free Radic Biol Med; 2010 Sep; 49(6):1099-108. PubMed ID: 20615462
[TBL] [Abstract][Full Text] [Related]
29. FK506 ameliorates cell death features in Huntington's disease striatal cell models.
Rosenstock TR; de Brito OM; Lombardi V; Louros S; Ribeiro M; Almeida S; Ferreira IL; Oliveira CR; Rego AC
Neurochem Int; 2011 Oct; 59(5):600-9. PubMed ID: 21703318
[TBL] [Abstract][Full Text] [Related]
30. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
31. Ethyl pyruvate ameliorates 3-nitropropionic acid-induced striatal toxicity through anti-neuronal cell death and anti-inflammatory mechanisms.
Jang M; Lee MJ; Cho IH
Brain Behav Immun; 2014 May; 38():151-65. PubMed ID: 24576481
[TBL] [Abstract][Full Text] [Related]
32. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
33. Decreased BDNF Release in Cortical Neurons of a Knock-in Mouse Model of Huntington's Disease.
Yu C; Li CH; Chen S; Yoo H; Qin X; Park H
Sci Rep; 2018 Nov; 8(1):16976. PubMed ID: 30451892
[TBL] [Abstract][Full Text] [Related]
34. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.
Lerner RP; Trejo Martinez Ldel C; Zhu C; Chesselet MF; Hickey MA
Brain Res Bull; 2012 Apr; 87(6):571-8. PubMed ID: 22326483
[TBL] [Abstract][Full Text] [Related]
35. A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.
Tidball AM; Bryan MR; Uhouse MA; Kumar KK; Aboud AA; Feist JE; Ess KC; Neely MD; Aschner M; Bowman AB
Hum Mol Genet; 2015 Apr; 24(7):1929-44. PubMed ID: 25489053
[TBL] [Abstract][Full Text] [Related]
36. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.
Kumar P; Kalonia H; Kumar A
Br J Pharmacol; 2011 Sep; 164(2b):644-54. PubMed ID: 21486276
[TBL] [Abstract][Full Text] [Related]
37. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
38. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
39. Huntington's disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent.
Joshi P; Bodnya C; Ilieva I; Neely MD; Aschner M; Bowman AB
Neurotoxicology; 2019 Dec; 75():148-157. PubMed ID: 31545971
[TBL] [Abstract][Full Text] [Related]
40. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
